Cardiotoxicities of paclitaxel in African Americans

Padma Kamineni, Kalpana Prakasa, Syed P. Hasan, Ravi Akula, Fitzroy Dawkins

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the cardiac disturbances in African-American patients treated with paclitaxel. Patients and Methods: One-hundred-nineteen African-American patients received paclitaxel for various cancers at Howard University Hospital during the years 1993-2001. Medical records of 100 patients were available for review. Sixty-seven percent were women and 33% were men. Ages ranged between 26-85 years (mean age 51 years). Medical records were reviewed for demographics, types of cancer, dosage and frequency of paclitaxel and other chemotherapeutic agents, events during paclitaxel infusion, initial and subsequent EKGs, and hospital admissions. We used the Chi-square test to compare EKG changes in patients with and without cardiac risk factors. Results: Ninety patients received paclitaxel as second-line chemotherapy, and 10 patients were treated with paclitaxel as a single agent. Dosage of paclitaxel ranged from 75-200 mg/square meter and was administered every 1-3 weeks. The electrocardiogram readings revealed the following cardiac events: 26% sinus tachycardia, 13% non-specific T-wave changes, 6% myocardial infarction, 4% prolonged QT interval, 4% left-bundle branch block, 3% right-bundle branch block, 3% sinus bradycardia, 2% premature atrial contractions, 2% premature ventricular contractions, 2% atrial flutter, and 1% atrial fibrillation. Eighty percent of the patients had risk factors for coronary artery disease. These cardiac disturbances were observed from day one to a maximum of eight years after receiving the chemotherapy and were independent of dosage of paclitaxel. Sixty percent of our study population had underlying co-morbid conditions, such as dehydration, anemia, sepsis, and hypoxia. The EKG changes observed in patients with underlying cardiac risk factors were statistically significant (p

Original languageEnglish (US)
Pages (from-to)977-981
Number of pages5
JournalJournal of the National Medical Association
Volume95
Issue number10
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Paclitaxel
African Americans
Electrocardiography
Bundle-Branch Block
Medical Records
Atrial Premature Complexes
Sinus Tachycardia
Cardiotoxicity
Drug Therapy
Atrial Flutter
Ventricular Premature Complexes
Chi-Square Distribution
Bradycardia
Dehydration
Atrial Fibrillation
Anemia
Reading
Coronary Artery Disease
Neoplasms
Sepsis

Keywords

  • Arrhythmia
  • Cardiotoxicities
  • Paclitaxel

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kamineni, P., Prakasa, K., Hasan, S. P., Akula, R., & Dawkins, F. (2003). Cardiotoxicities of paclitaxel in African Americans. Journal of the National Medical Association, 95(10), 977-981.

Cardiotoxicities of paclitaxel in African Americans. / Kamineni, Padma; Prakasa, Kalpana; Hasan, Syed P.; Akula, Ravi; Dawkins, Fitzroy.

In: Journal of the National Medical Association, Vol. 95, No. 10, 10.2003, p. 977-981.

Research output: Contribution to journalArticle

Kamineni, P, Prakasa, K, Hasan, SP, Akula, R & Dawkins, F 2003, 'Cardiotoxicities of paclitaxel in African Americans', Journal of the National Medical Association, vol. 95, no. 10, pp. 977-981.
Kamineni P, Prakasa K, Hasan SP, Akula R, Dawkins F. Cardiotoxicities of paclitaxel in African Americans. Journal of the National Medical Association. 2003 Oct;95(10):977-981.
Kamineni, Padma ; Prakasa, Kalpana ; Hasan, Syed P. ; Akula, Ravi ; Dawkins, Fitzroy. / Cardiotoxicities of paclitaxel in African Americans. In: Journal of the National Medical Association. 2003 ; Vol. 95, No. 10. pp. 977-981.
@article{4b2f45ccfe1d4e268771f9ae5947e1e2,
title = "Cardiotoxicities of paclitaxel in African Americans",
abstract = "Purpose: To assess the cardiac disturbances in African-American patients treated with paclitaxel. Patients and Methods: One-hundred-nineteen African-American patients received paclitaxel for various cancers at Howard University Hospital during the years 1993-2001. Medical records of 100 patients were available for review. Sixty-seven percent were women and 33{\%} were men. Ages ranged between 26-85 years (mean age 51 years). Medical records were reviewed for demographics, types of cancer, dosage and frequency of paclitaxel and other chemotherapeutic agents, events during paclitaxel infusion, initial and subsequent EKGs, and hospital admissions. We used the Chi-square test to compare EKG changes in patients with and without cardiac risk factors. Results: Ninety patients received paclitaxel as second-line chemotherapy, and 10 patients were treated with paclitaxel as a single agent. Dosage of paclitaxel ranged from 75-200 mg/square meter and was administered every 1-3 weeks. The electrocardiogram readings revealed the following cardiac events: 26{\%} sinus tachycardia, 13{\%} non-specific T-wave changes, 6{\%} myocardial infarction, 4{\%} prolonged QT interval, 4{\%} left-bundle branch block, 3{\%} right-bundle branch block, 3{\%} sinus bradycardia, 2{\%} premature atrial contractions, 2{\%} premature ventricular contractions, 2{\%} atrial flutter, and 1{\%} atrial fibrillation. Eighty percent of the patients had risk factors for coronary artery disease. These cardiac disturbances were observed from day one to a maximum of eight years after receiving the chemotherapy and were independent of dosage of paclitaxel. Sixty percent of our study population had underlying co-morbid conditions, such as dehydration, anemia, sepsis, and hypoxia. The EKG changes observed in patients with underlying cardiac risk factors were statistically significant (p",
keywords = "Arrhythmia, Cardiotoxicities, Paclitaxel",
author = "Padma Kamineni and Kalpana Prakasa and Hasan, {Syed P.} and Ravi Akula and Fitzroy Dawkins",
year = "2003",
month = "10",
language = "English (US)",
volume = "95",
pages = "977--981",
journal = "Journal of the National Medical Association",
issn = "0027-9684",
publisher = "National Medical Association",
number = "10",

}

TY - JOUR

T1 - Cardiotoxicities of paclitaxel in African Americans

AU - Kamineni, Padma

AU - Prakasa, Kalpana

AU - Hasan, Syed P.

AU - Akula, Ravi

AU - Dawkins, Fitzroy

PY - 2003/10

Y1 - 2003/10

N2 - Purpose: To assess the cardiac disturbances in African-American patients treated with paclitaxel. Patients and Methods: One-hundred-nineteen African-American patients received paclitaxel for various cancers at Howard University Hospital during the years 1993-2001. Medical records of 100 patients were available for review. Sixty-seven percent were women and 33% were men. Ages ranged between 26-85 years (mean age 51 years). Medical records were reviewed for demographics, types of cancer, dosage and frequency of paclitaxel and other chemotherapeutic agents, events during paclitaxel infusion, initial and subsequent EKGs, and hospital admissions. We used the Chi-square test to compare EKG changes in patients with and without cardiac risk factors. Results: Ninety patients received paclitaxel as second-line chemotherapy, and 10 patients were treated with paclitaxel as a single agent. Dosage of paclitaxel ranged from 75-200 mg/square meter and was administered every 1-3 weeks. The electrocardiogram readings revealed the following cardiac events: 26% sinus tachycardia, 13% non-specific T-wave changes, 6% myocardial infarction, 4% prolonged QT interval, 4% left-bundle branch block, 3% right-bundle branch block, 3% sinus bradycardia, 2% premature atrial contractions, 2% premature ventricular contractions, 2% atrial flutter, and 1% atrial fibrillation. Eighty percent of the patients had risk factors for coronary artery disease. These cardiac disturbances were observed from day one to a maximum of eight years after receiving the chemotherapy and were independent of dosage of paclitaxel. Sixty percent of our study population had underlying co-morbid conditions, such as dehydration, anemia, sepsis, and hypoxia. The EKG changes observed in patients with underlying cardiac risk factors were statistically significant (p

AB - Purpose: To assess the cardiac disturbances in African-American patients treated with paclitaxel. Patients and Methods: One-hundred-nineteen African-American patients received paclitaxel for various cancers at Howard University Hospital during the years 1993-2001. Medical records of 100 patients were available for review. Sixty-seven percent were women and 33% were men. Ages ranged between 26-85 years (mean age 51 years). Medical records were reviewed for demographics, types of cancer, dosage and frequency of paclitaxel and other chemotherapeutic agents, events during paclitaxel infusion, initial and subsequent EKGs, and hospital admissions. We used the Chi-square test to compare EKG changes in patients with and without cardiac risk factors. Results: Ninety patients received paclitaxel as second-line chemotherapy, and 10 patients were treated with paclitaxel as a single agent. Dosage of paclitaxel ranged from 75-200 mg/square meter and was administered every 1-3 weeks. The electrocardiogram readings revealed the following cardiac events: 26% sinus tachycardia, 13% non-specific T-wave changes, 6% myocardial infarction, 4% prolonged QT interval, 4% left-bundle branch block, 3% right-bundle branch block, 3% sinus bradycardia, 2% premature atrial contractions, 2% premature ventricular contractions, 2% atrial flutter, and 1% atrial fibrillation. Eighty percent of the patients had risk factors for coronary artery disease. These cardiac disturbances were observed from day one to a maximum of eight years after receiving the chemotherapy and were independent of dosage of paclitaxel. Sixty percent of our study population had underlying co-morbid conditions, such as dehydration, anemia, sepsis, and hypoxia. The EKG changes observed in patients with underlying cardiac risk factors were statistically significant (p

KW - Arrhythmia

KW - Cardiotoxicities

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0142031082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142031082&partnerID=8YFLogxK

M3 - Article

C2 - 14620711

AN - SCOPUS:0142031082

VL - 95

SP - 977

EP - 981

JO - Journal of the National Medical Association

JF - Journal of the National Medical Association

SN - 0027-9684

IS - 10

ER -